var data={"title":"Gabapentin: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Gabapentin: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6246?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=gabapentin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Gabapentin: Patient drug information&quot;</a> and <a href=\"topic.htm?path=gabapentin-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Gabapentin: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F175023\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Fanatrex FusePaq;</li>\n      <li>Gralise;</li>\n      <li>Gralise Starter;</li>\n      <li>Neuraptine;</li>\n      <li>Neurontin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50769812\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Neurontin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F175060\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Anticonvulsant, Miscellaneous;</li>\n      <li>\n        GABA Analog</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F175027\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Postherpetic neuralgia:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immediate release: Day 1: 300 mg, Day 2: 300 mg twice daily, Day 3: 300 mg 3 times daily; dose may be titrated as needed for pain relief (range: 1,800 to 3,600 mg/day in divided doses, daily doses &gt;1,800 mg do not generally show greater benefit)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended release: Day 1: 300 mg, Day 2: 600 mg, Days 3 to 6: 900 mg once daily, Days 7 to 10: 1,200 mg once daily, Days 11 to 14: 1,500 mg once daily, Days &ge;15: 1,800 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Seizures, partial onset:</b> Oral: Immediate release:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Initial:</i> 300 mg 3 times daily; increase dosage based on response and tolerability; usual dosage: 900 to 1,800 mg/day administered in 3 divided doses; doses of up to 2,400 mg/day have been tolerated in long-term clinical studies; up to 3,600 mg/day has been tolerated in short-term studies</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> If gabapentin is discontinued or if another anticonvulsant is added to therapy, it should be done slowly over a minimum of 1 week.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Alcohol dependence (off-label use): </b>Oral: Immediate release: 300 mg once daily on day 1, followed by dosage escalation, based on response and tolerability, in increments of 300 mg/day up to a target dose of 1,800 mg/day in 3 divided doses (Brower 2008; Mason 2014; VA/DoD 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Alcohol withdrawal (off-label use):</b> Oral: Immediate release: 300 to 400 mg 3 times daily on days 1 through 3, then 300 to 400 mg twice daily on day 4, then discontinue. For breakthrough symptoms during days 1 through 4, consider providing single doses of 100 mg administered up to 3 times daily and a 300 mg dose reserved for the evening (Myrick 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Brachioradial pruritus (off-label use): </b>Oral: Immediate release: Initial: 100 mg 3 times daily; increase dose based on response and tolerability up to 1,800 mg/day (Bueller 1999; Kanitakis 2006; Winhoven 2004; Yilmaz 2010). Additional data may be necessary to further define the role of gabapentin in this condition.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cough, chronic (refractory) (off-label use):</b> Oral: Immediate release: 300 mg once daily on day 1, followed by dosage escalation in increments of 300 mg/day until cough symptoms cease, side effects are intolerable, or a maximum tolerated dose of 1,800 mg/day given in 2 divided doses is reached (ACCP [Gibson 2016]; Ryan 2012). Additional data may be necessary to further define the role of gabapentin in this condition.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Diabetic neuropathy (off-label use):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immediate release: Initial: 100 to 300 mg 1 to 3 times daily; target dose: 900 to 3,600 mg/day (AAN [Bril 2011]; ADA [Pop-Busui 2017]; EFNS [Attal 2010]; IASP [Finnerup 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended release: Initial: 300 mg at bedtime; increase dose based on efficacy and tolerability over 2 weeks to a target dose of 3,000 to 3,600 mg/day (IASP [Finnerup 2015]; Sandercock 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Fibromyalgia syndrome (off-label use):</b> Oral: Immediate release: Initial: 300 mg once daily at bedtime, increase in increments of 300 to 600 mg/day every 1 to 2 weeks based on response and tolerability up to 2,400 mg/day in divided doses. Median dosage in clinical trial was 1,800 mg/day with a range of 1,200 to 2,400 mg/day (Arnold 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hiccups (singultus) (off-label use):</b> Oral: Immediate release: Initial: 300 to 1,200 mg divided 3 to 4 times daily for short-term or continuous therapy <b>or</b> 300 to 400 mg 3 times a day for up to 3 days, followed by 400 mg 3 times a day for 3 additional days. Some regimens have used short-term therapy (6 days) as needed and others have used continuous therapy (Hernandez 2004; Jatzko 2007; Moretti 2004; Porzio 2010; Schuchmann 2007). Additional data may be necessary to further define the role of gabapentin in this condition.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hot flashes (off-label use):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immediate release: Initial: 300 to 400 mg once daily at bedtime; may initiate with 100 mg at bedtime if concerned about adverse reactions; increase over 3 to 12 days based on response and tolerability up to 600 to 2,400 mg/day in 2 to 3 divided doses (ACOG 2014; NAMS 2015; Reddy 2006, Toulis 2009). In the study involving men with prostate cancer, dose was titrated by 300 mg every 7 days to 300 mg 3 times daily (Loprinzi 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended release: Target dose: 600 mg in the morning and 1,200 mg at bedtime; increase to target dose over 1 week (Pinkerton 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Neuropathic pain (off-label use):</b> Oral: Immediate release: 1,200 to 3,600 mg/day in 3 divided doses (IASP [Finnerup 2015]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Critically ill patients:</i> Oral: Immediate release: Initial: 100 mg 3 times daily in combination with IV opioids; maintenance: 300 to 1,200 mg 3 times daily; maximum dose: 3,600 mg daily (SCCM [Barr 2013])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Postoperative pain (adjunct) (off-label use):</b> Oral: Immediate release: 300 to 1,200 mg given the night before, 1 to 2 hours prior to surgery or immediately following surgery (Doleman 2015; Peng 2007; Yu 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Restless legs syndrome (RLS) (off-label use):</b> Oral: Immediate release: Initial: 300 mg once daily 2 hours before bedtime. Doses &ge;600 mg/day have been given in 2 divided doses (late afternoon and 2 hours before bedtime). Dose may be titrated every 2 weeks until symptom relief achieved (range: 300 to 2,400 mg/day). Suggested maintenance dosing schedule: One-third of total daily dose given at 12 pm, remaining two-thirds total daily dose given at 8 pm (Garcia-Borreguero 2016; Happe 2003; Saletu 2010; Vignatelli 2006).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Social anxiety disorder (off-label use):</b> Oral: Immediate release: Initial: 300 mg twice daily; increase dose based on response and tolerability in increments of no more than 300 mg/day up to a maximum of 3,600 mg/day given in 3 divided doses. Doses for responders ranged from 900 to 3,600 mg/day in the clinical trial (Pande 1999). Additional data may be necessary to further define the role of gabapentin in this condition.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Uremic pruritus (off-label use)</b>: Oral: Immediate release: Initial: 100 mg after dialysis on hemodialysis days; may increase dose based on response and tolerability up to 400 mg after dialysis on hemodialysis days (Gunal 2004; Naini 2007; Nofal 2016; Razeghi 2009).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50991466\" class=\"block dora drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment (Adult)</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Estimation of renal function for dosing adjustments should be done using the Cockcroft-Gault formula.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immediate release:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &ge;60 mL/minute: 300 to 1,200 mg 3 times daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &gt;30 to 59 mL/minute: 200 to 700 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &gt;15 to 29 mL/minute: 200 to 700 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 15 mL/minute: 100 to 300 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &lt;15 mL/minute: Reduce daily dose in proportion to creatinine clearance based on dose for creatinine clearance of 15 mL/minute (eg, reduce dose by one-half [range: 50 to 150 mg/day] for CrCl 7.5 mL/minute)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">ESRD requiring hemodialysis: Dose based on CrCl plus a single supplemental dose of 125 to 350 mg (given after each 4 hours of hemodialysis)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended release: <b>Note:</b> Follow initial dose titration schedule if treatment-naive.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &ge;60 mL/minute: 1,800 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &gt;30 to 59 mL/minute: 600 to 1,800 mg once daily; dependent on tolerability and clinical response</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &lt;30 mL/minute: Use is not recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">ESRD requiring hemodialysis: Use is not recommended.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50988788\" class=\"block doha drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment (Adult)</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling; however, gabapentin is not hepatically metabolized.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F175044\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=gabapentin-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Gabapentin: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Seizures, partial onset:</b> Immediate release: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 3 to 4 years: Oral: Initial: 10 to 15 mg/kg/day in 3 divided doses; titrate to effective dose over ~3 days; increase dosage based on response and tolerability; usual dosage: 40 mg/kg/day in 3 divided doses; dosages of up to 50 mg/kg/day have been tolerated in clinical studies:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 5 to 11 years: Oral: Initial: 10 to 15 mg/kg/day in 3 divided doses; titrate to effective dose over ~3 days; increase dosage based on response and tolerability; usual dosage: 25 to 35 mg/kg/day in 3 divided doses; dosages of up to 50 mg/kg/day have been tolerated in clinical studies</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &ge;12 years and Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> If gabapentin is discontinued or if another anticonvulsant is added to therapy, it should be done slowly over a minimum of 1 week</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51110605\" class=\"block dorp drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment (Pediatric)</span>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immediate release:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &lt;12 years: There are no dosing adjustments provided in the manufacturer&rsquo;s labeling (has not been studied).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;12 years and Adolescents: See table.</p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <caption style=\"text-align:center;\">Gabapentin Dosing Adjustments in Renal Impairment</caption>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <thead valign=\"middle\">\n        <tr>\n          <th valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">Creatinine Clearance</p>\n            <p style=\"text-indent:0em;\">(mL/min)</p></th>\n          <th valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">Total Daily Dose Range</p>\n            <p style=\"text-indent:0em;\">(mg/day)</p></th>\n          <th colspan=\"5\" valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">Dosage Regimens</p>\n            <p style=\"text-indent:0em;\">(Maintenance Doses)</p>\n            <p style=\"text-indent:0em;\">(mg)</p></th></tr></thead>\n      <tfoot valign=\"middle\">\n        <tr>\n          <td colspan=\"7\" align=\"left\">\n            <p style=\"text-indent:0em;\">\n              <sup>a</sup>CrCl &lt;15 mL/minute: Reduce daily dose in proportion to creatinine clearance.</p></td></tr>\n        <tr>\n          <td colspan=\"7\" align=\"left\">\n            <p style=\"text-indent:0em;\">\n              <sup>b</sup>Supplemental dose should be administered after each 4 hours of hemodialysis (patients on hemodialysis should also receive maintenance doses based on renal function as listed in the upper portion of the table).</p></td></tr></tfoot>\n      <tbody valign=\"top\">\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&ge;60</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">900 to 3,600</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">300</p>\n            <p style=\"text-indent:0em;\">3 times/day</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">400</p>\n            <p style=\"text-indent:0em;\">3 times/day</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">600</p>\n            <p style=\"text-indent:0em;\">3 times/day</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">800</p>\n            <p style=\"text-indent:0em;\">3 times/day</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1,200</p>\n            <p style=\"text-indent:0em;\">3 times/day</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&gt;30 to 59</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">400 to 1,400</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">200 twice daily</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">300 twice daily</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">400 twice daily</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">500 twice daily</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">700 twice daily</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&gt;15 to 29</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">200 to 700</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">200 daily</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">300 daily</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">400 daily</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">500 daily</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">700 daily</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">15<sup>a</sup></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">100 to 300</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">100 daily</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">125 daily</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">150 daily</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">200 daily</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">300 daily</p></td></tr>\n        <tr>\n          <td colspan=\"2\" rowspan=\"2\" valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <b>Hemodialysis<sup>b</sup></b></p></td>\n          <td colspan=\"5\" align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <b>Posthemodialysis Supplemental Dose</b></p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">125 mg</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">150 mg</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">200 mg</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">250 mg</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">350 mg</p></td></tr></tbody></table>\n    </div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51110606\" class=\"block dohp drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment (Pediatric)</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; however, adjustment not necessary since gabapentin is not hepatically metabolized.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F175028\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing. In the off-label management of restless legs syndrome, a starting dose of 100 mg once daily in patients &gt;65 years has been recommended (Garcia-Borreguero 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F174997\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neurontin: 100 mg, 300 mg, 400 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 100 mg, 300 mg, 400 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cream, External: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neuraptine: 10% (30 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Miscellaneous, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gralise Starter: 300 &amp; 600 mg (78 ea) [contains soybean lecithin]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neurontin: 250 mg/5 mL (470 mL) [strawberry anise flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 250 mg/5 mL (5 mL, 470 mL, 473 mL); 300 mg/6 mL (6 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Fanatrex FusePaq: 25 mg/mL (420 mL) [contains saccharin sodium, sodium benzoate]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gralise: 300 mg [contains soybean lecithin]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gralise: 600 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neurontin: 600 mg, 800 mg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 600 mg, 800 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F174981\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28799619\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gralise is the extended release formulation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fanatrex FusePaq is a compounding kit for the preparation of an oral suspension. Refer to manufacturer's labeling for compounding instructions.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuraptine cream is compounded from a kit. Refer to manufacturer's labeling for compounding instructions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10916634\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neurontin: <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM229208.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/+Btau8Jzc5BLV85NUiGV68rYi5XW2D09twyH6QySiWIw==&amp;TOPIC_ID=8483\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM229208.pdf</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gralise: <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM245196.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/+Btau8Jzc5BLV85NUiGV68miQs1AlzdgDYd0nnv+jv0A==&amp;TOPIC_ID=8483\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM245196.pdf</a></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F175001\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immediate release: May administer without regards to meals. Administer first dose on first day at bedtime to avoid somnolence and dizziness. Dosage must be adjusted for renal function; when given 3 times daily, the maximum time between doses should not exceed 12 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Extended release: Administer with evening meal. Swallow whole; do not chew, crush, or split.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F175000\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Postherpetic neuralgia:</b> Management of postherpetic neuralgia (PHN) in adults.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Seizures, partial onset (immediate release only):</b> As adjunctive therapy in the treatment of partial seizures with and without secondary generalization in adults and pediatric patients 3 years and older with epilepsy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25726013\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Alcohol dependence; Alcohol withdrawal; Brachioradial pruritus; Cough, chronic (refractory); Diabetic neuropathy; Fibromyalgia syndrome; Hiccups (singultus); Hot flashes; Neuropathic pain; Post-operative pain (adjunct); Restless legs syndrome; Social anxiety disorder; Uremic pruritus</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F175068\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Neurontin may be confused with Motrin, Neoral, nitrofurantoin, Noroxin [DSC],  Zarontin</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F174988\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">As reported for immediate release (IR) formulations in patients &gt;12 years of age, unless otherwise noted in children (3 to 12 years) or with use of Gralise</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Dizziness (IR: 17% to 28%; children 3%; Gralise: 11%), drowsiness (IR: 19% to 21%; children 8%; Gralise: 5%), ataxia (1% to 13%), fatigue (11%; children 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Viral infection (children 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Peripheral edema (IR: 2% to 8%; Gralise: 4%), vasodilatation (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Hostility (children 5% to 8%), tremor (7%), emotional lability (children 4% to 6%), hyperkinesia (children 3% to 5%), headache (children and adolescents &gt;2%), abnormality in thinking (2% to 3%; children 2%), abnormal gait (2%), amnesia (2%), depression (2%), nervousness (2%), pain (Gralise: 1% to 2%), hyperesthesia (1%), lethargy (Gralise: 1%), twitching (1%), vertigo (Gralise: 1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Pruritus (1%), skin rash (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Weight gain (IR: Adults and children 2% to 3%; Gralise: 2%), hyperglycemia (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Diarrhea (IR: 6%), nausea and vomiting (3% to 4%; children 8%), xerostomia (IR: 2% to 5%; Gralise: 3%), constipation (IR: 1% to 4%; Gralise: 1%), abdominal pain (3%), dyspepsia (IR: 2%; Gralise: 1%), dry throat (2%), dental disease (2%), flatulence (2%), increased appetite (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Impotence (2%), urinary tract infection (Gralise: 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Decreased white blood cell count (1%), leukopenia (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Infection (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Weakness (6%), back pain (IR: 2%; Gralise: 2%), dysarthria (2%), limb pain (Gralise: 2%), myalgia (2%), bone fracture (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Nystagmus (8%), diplopia (1% to 6%), amblyopia (4%), blurred vision (3% to 4%), conjunctivitis (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Otic: Otitis media (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Rhinitis (4%), bronchitis (children 3%), nasopharyngitis (Gralise: 3%), respiratory tract infection (children 3%), pharyngitis (1% to 3%), cough (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (children 10%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Postmarketing and case reports: Abnormal hepatic function, acute renal failure, agitation, altered serum glucose, anaphylaxis, anemia, angina pectoris, angioedema, aphasia, aspiration pneumonia, blindness, blood coagulation disorder, bradycardia, brain disease, breast hypertrophy, bronchospasm, cardiac arrhythmia (various), cerebrovascular accident, change in libido, cholestatic hepatitis, CNS neoplasm, colitis, confusion, Cushingoid appearance, DRESS syndrome, drug abuse, drug dependence, dyspnea, ejaculatory disorder, erythema multiforme, facial paralysis, falling, fecal incontinence, fulminant hepatitis, gastroenteritis, glaucoma, glycosuria, gynecomastia, hearing loss, heart block, hematemesis, hematuria, hemiplegia, hemorrhage, hepatitis, hepatomegaly, herpes zoster, hyperlipidemia, hypersensitivity reaction, hypertension, hyperthyroidism, hyperventilation, hypoglycemia, hyponatremia, hypotension, hypothyroidism, hypoventilation, increased creatine phosphokinase, increased liver enzymes, increased serum creatinine, jaundice, joint swelling, leukocytosis, loss of consciousness, lymphadenopathy, lymphocytosis, memory impairment, meningism, migraine, movement disorder, myocardial infarction, myoclonus (local), nephrolithiasis, nephrosis, nerve palsy, non-Hodgkin lymphoma, ovarian failure, palpitations, pancreatitis, paresthesia, peptic ulcer, pericardial effusion, pericardial rub, pericarditis, peripheral vascular disease, pneumonia, psychosis, pulmonary edema, pulmonary thromboembolism, purpura, retinopathy, rhabdomyolysis, seasonal allergy, sexual disorder, skin necrosis, status epilepticus, Stevens-Johnson syndrome, subdural hematoma, suicidal ideation, suicidal tendencies, syncope, tachycardia, thrombocytopenia, thrombophlebitis, tumor growth, withdrawal syndrome</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F175005\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to gabapentin or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F174985\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anaphylaxis/angioedema: May occur after the first dose or at any time during treatment. Discontinue therapy and seek immediate medical care if signs or symptoms of anaphylaxis or angioedema occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS depression: May cause CNS depression including somnolence and dizziness, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Multiorgan hypersensitivity: Potentially serious, sometimes fatal multiorgan hypersensitivity (also known as drug reaction with eosinophilia and systemic symptoms [DRESS]) has been reported with some antiepileptic drugs, including gabapentin. Monitor for signs and symptoms of possible disparate manifestations associated with lymphatic, hepatic, renal, cardiac, and/or hematologic systems; fever, rash, and eosinophilia may also be present. Discontinue immediately if suspected.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neuropsychiatric effects: Use in pediatric patients with epilepsy has been associated with the occurrence of CNS adverse effects of mild to moderate intensity. The most significant include emotional lability, hostility (eg, aggressive behaviors), changes in behavior and thinking (eg, concentration problems and changes in school performance), and hyperkinesia (primarily restlessness and hyperactivity).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Suicidal ideation: Pooled analysis of trials involving various antiepileptics (regardless of indication) showed an increased risk of suicidal thoughts/behavior (incidence rate: 0.43% treated patients compared to 0.24% of patients receiving placebo); risk observed as early as 1 week after initiation and continued through duration of trials (most trials &le;24 weeks). Monitor all patients for notable changes in behavior that might indicate suicidal thoughts or depression; notify healthcare provider immediately if symptoms occur.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with severe renal impairment; dose adjustment required.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizure disorder: The safety and efficacy of the extended release formulation has not been studied in patients with epilepsy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Product interchangeability: Immediate release and extended release products are not interchangeable with each other or with gabapentin enacarbil due to differences in formulations, indications, and pharmacokinetics.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tumorigenic potential: Male rat studies demonstrated an association with pancreatic adenocarcinoma (clinical implication in humans is unknown).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Withdrawal: Anticonvulsants should not be discontinued abruptly because of the possibility of increasing seizure frequency; therapy should be withdrawn gradually to minimize the potential of increased seizure frequency, unless safety concerns require a more rapid withdrawal. The extended release formulation should be withdrawn over &ge;1 week.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299373\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F174990\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8483&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antacids: May decrease the serum concentration of Gabapentin. Management: Administer gabapentin at least 2 hours after antacid administration.  Monitor patients closely for evidence of reduced response to gabapentin therapy when both of these drugs are being used.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromopride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine patches (Butrans brand) at 5 mcg/hr in adults when used with other CNS depressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabis: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxylamine: May enhance the CNS depressant effect of CNS Depressants. Management: The manufacturer of Diclegis (doxylamine/pyridoxine), intended for use in pregnancy, specifically states that use with other CNS depressants is  not recommended.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HYDROcodone: CNS Depressants may enhance the CNS depressant effect of HYDROcodone.  Management: Avoid concomitant use of hydrocodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Kava Kava: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium Salts: May enhance the CNS depressant effect of Gabapentin. Specifically, high dose intravenous/epidural magnesium sulfate may enhance the CNS depressant effects of gabapentin. Magnesium Salts may decrease the serum concentration of Gabapentin. Management: Administer gabapentin at least 2 hours after oral magnesium salts administration.  Monitor patients closely for evidence of reduced response to gabapentin therapy. Monitor for CNS depression if high dose IV/epidural magnesium sulfate is used.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mefloquine: May diminish the therapeutic effect of Anticonvulsants. Mefloquine may decrease the serum concentration of Anticonvulsants. Management: Mefloquine is contraindicated for malaria prophylaxis in persons with a history of convulsions.  Monitor anticonvulsant concentrations and treatment response closely with concurrent use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mianserin: May diminish the therapeutic effect of Anticonvulsants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Minocycline: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Morphine (Systemic): Gabapentin may enhance the CNS depressant effect of Morphine (Systemic). Morphine (Systemic) may increase the serum concentration of Gabapentin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioid Analgesics: CNS Depressants may enhance the CNS depressant effect of Opioid Analgesics.  Management: Avoid concomitant use of opioid analgesics and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orlistat: May decrease the serum concentration of Anticonvulsants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tapentadol: May enhance the CNS depressant effect of CNS Depressants. Management: Avoid concomitant use of tapentadol and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetrahydrocannabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trimeprazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F175018\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Tablet, solution (immediate release): No significant effect on rate or extent of absorption; extended release tablet: Increases rate and extent of absorption. Management: Administer immediate release products without regard to food. Administer extended release with food.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F174993\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F175008\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in animal reproduction studies. Gabapentin crosses the placenta. In a small study (n=6), the umbilical/maternal plasma concentration ratio was ~1.74. Neonatal concentrations declined quickly after delivery and at 24 hours of life were ~27% of the cord blood concentrations at birth (gabapentin neonatal half-life ~14 hours) (Ohman 2005). Pregnancy registry outcome data following maternal use of gabapentin during pregnancy is limited (Holmes 2012). Folic acid supplementation is recommended prior to and during pregnancy in women using gabapentin (Borgelt 2016; Picchietti 2015). Gabapentin is used for the treatment of restless leg syndrome; however, current guidelines note there is insufficient evidence to recommend its use in pregnant women for this indication (Picchietti 2015).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Patients exposed to gabapentin during pregnancy are encouraged to enroll in the North American Antiepileptic Drug (NAAED) Pregnancy Registry by calling 1-888-233-2334. Additional information is available at www.aedpregnancyregistry.org.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F175009\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Gabapentin is present in breast milk.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The relative infant dose (RID) of gabapentin is 8.7% to 13% when calculated using the highest breast milk concentration located and compared to an infant therapeutic dose of 10 to 15 mg/kg/day. In general, breastfeeding is considered acceptable when the RID is &lt;10%; when an RID is &gt;25% breastfeeding should generally be avoided (Anderson 2016; Ito 2000).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The RID of gabapentin was calculated using a milk concentration of 8.7 mcg/mL, providing an estimated daily infant dose via breast milk of 1.3 mg/kg/day. This milk concentration was obtained following maternal administration of oral gabapentin 2,100 mg/day. Gabapentin was detected in the serum of two breastfeeding infants 2 to 3 weeks after delivery and in one infant after 3 months of breastfeeding. Adverse events were not reported in the breastfed infants (Ohman 2005).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Manufacturer recommendations may vary; the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother. Based on limited information, gabapentin is considered relatively compatible with breastfeeding; infants should be monitored for drowsiness, adequate weight gain, and developmental milestones (Davanzo 2013; Veiby 2015). Available guidelines state gabapentin may be considered for the treatment of refractory restless leg syndrome in breastfeeding women (Picchietti 2015).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F175010\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Extended release tablet should be taken with food.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F174995\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Periodic renal function, suicidality (eg, suicidal thoughts, depression, behavioral changes)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F174984\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Gabapentin is structurally related to GABA. However, it does not bind to GABA<sub>A</sub> or GABA<sub>B</sub> receptors, and it does not appear to influence synthesis or uptake of GABA. High affinity gabapentin binding sites have been located throughout the brain; these sites correspond to the presence of voltage-gated calcium channels specifically possessing the alpha-2-delta-1 subunit. This channel appears to be located presynaptically, and may modulate the release of excitatory neurotransmitters which participate in epileptogenesis and nociception.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F175004\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Variable, from proximal small bowel by L-amino transport system; saturable process; dose-dependent</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: 58 &plusmn; 6 L; CSF concentrations are ~20% of plasma concentrations</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: &lt;3%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Not metabolized</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: Inversely proportional to dose due to saturable absorption:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immediate release:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">900 mg/day: 60%</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">1,200 mg/day: 47%</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">2,400 mg/day: 34%</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">3,600 mg/day: 33%</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">4,800 mg/day: 27%</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended release: Variable; increased with higher fat content meal</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants 1 month to Children 12 years: 4.7 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults, normal: 5 to 7 hours; increased half-life with decreased renal function; anuric adult patients: 132 hours; adults during hemodialysis: 3.8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak: Immediate release: Infants 1 month to Children 12 years: 2 to 3 hours; Adults: 2 to 4 hours; Extended release: 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Proportional to renal function; urine (as unchanged drug)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Clearance: Apparent oral clearance is directly proportional to CrCl: Clearance in infants is highly variable; oral clearance (per kg) in children &lt;5 years of age is higher than in children &ge;5 years of age</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51196078\" class=\"block phksp drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics: Additional Considerations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal function impairment: In CrCl &lt;30 mL/minute, half-life is approximately 52 hours (immediate release). In moderate and severe renal impairment, Cl was decreased to 3 and 1 L/hour, respectively, compared with 5 to 7 L/hour in nonrenal impairment patients (ER).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F175007\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Gabapentin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (100): $53.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg (100): $133.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400 mg (100): $159.70</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Neurontin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (100): $255.05</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg (50): $348.68</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400 mg (50): $404.88</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Cream</b> (Neuraptine External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10% (30 mL): $195.37</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Misc</b> (Gralise Starter Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 &amp; 600 mg (78): $722.84</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Gabapentin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg/5 mL (470 mL): $148.91</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Neurontin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg/5 mL (470 mL): $475.66</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (Fanatrex FusePaq Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg/mL (420 mL): $490.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Gabapentin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">600 mg (100): $252.62</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">800 mg (100): $303.15</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Gralise Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg (90): $834.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">600 mg (90): $834.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Neurontin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">600 mg (100): $1,211.42</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">800 mg (100): $1,453.52</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F175011\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Alpentin (ID);</li>\n      <li>Anatin (LK);</li>\n      <li>Bapex (MX);</li>\n      <li>Barontin (KR);</li>\n      <li>Bineurox (VN);</li>\n      <li>Blugat (MX);</li>\n      <li>Calmpent (PH);</li>\n      <li>Carbatin (TW);</li>\n      <li>Die Li (CN);</li>\n      <li>Dineurin (CL);</li>\n      <li>Dineurol (PY);</li>\n      <li>Engaba (PK);</li>\n      <li>Epiven (ID, MY, PH);</li>\n      <li>Epleptin (ZA);</li>\n      <li>Etoclon (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>G-Pentin (TH);</li>\n      <li>Gabadin (PY);</li>\n      <li>Gabagamma (LV);</li>\n      <li>Gabalept (RO);</li>\n      <li>Gabamax (BD);</li>\n      <li>Gabanet (JO, LB, QA);</li>\n      <li>Gabantin (MX);</li>\n      <li>Gabapen (JP);</li>\n      <li>Gabapenin (KR);</li>\n      <li>Gabaran (AU);</li>\n      <li>Gabaron (PH);</li>\n      <li>Gabasant (ID);</li>\n      <li>Gabatin (CH, KR, LK);</li>\n      <li>Gabatine (AU);</li>\n      <li>Gabator (PH, TZ, ZW);</li>\n      <li>Gabatrex (QA);</li>\n      <li>Gabavex (PH);</li>\n      <li>Gabenil (HK);</li>\n      <li>Gabictal (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Gabin (IE);</li>\n      <li>Gabix (PH);</li>\n      <li>Gabon (BD);</li>\n      <li>Gabutin (TH);</li>\n      <li>Gantin (AU);</li>\n      <li>Gapatin (TW);</li>\n      <li>Gapridol (MX);</li>\n      <li>Gaty (TW);</li>\n      <li>Gonnaz (PH);</li>\n      <li>Gordius (LV);</li>\n      <li>Habamaks (UA);</li>\n      <li>Hrymodyn (UA);</li>\n      <li>Meditan (UA);</li>\n      <li>Mirgy (VN);</li>\n      <li>Nepsy (BD);</li>\n      <li>Neuleptol (KR);</li>\n      <li>Neupentin (LK);</li>\n      <li>Neuran (HK, MY);</li>\n      <li>Neuril (DK);</li>\n      <li>Neurontin (AE, AR, AT, AU, BB, BE, BG, BH, BO, BR, CH, CN, CO, CY, CZ, DE, EC, EE, EG, ES, FI, FR, GB, GR, HK, HR, HU, ID, IE, IL, IN, IQ, IR, IS, IT, JO, KE, KR, KW, LB, LT, LU, LV, LY, MT, MX, MY, NL, NO, NZ, OM, PE, PH, PL, PR, PT, QA, RU, SA, SE, SG, SI, SK, SY, TH, TR, TW, UY, VE, VN, YE, ZA);</li>\n      <li>Neuropen (BD);</li>\n      <li>Neurostil (IE);</li>\n      <li>New-GABA (KR);</li>\n      <li>Neyralhin (UA);</li>\n      <li>Nopatic (MX);</li>\n      <li>Nupentin (AU, NZ, SG);</li>\n      <li>Nurona (JO, LB);</li>\n      <li>Opipentin (ID);</li>\n      <li>Pendine (AU);</li>\n      <li>Pengatine (KR);</li>\n      <li>Penral (LK);</li>\n      <li>Reinin (PH);</li>\n      <li>Remaltin (TW);</li>\n      <li>Rontin (TH);</li>\n      <li>Sipentin (ID);</li>\n      <li>Tebantin (VN);</li>\n      <li>Volar (JO, LB);</li>\n      <li>Vultin (HK, TH);</li>\n      <li>Vultin 600 (TH)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24463691\"></a>ACOG Practice Bulletin No. 141: management of menopausal symptoms. <i>Obstet Gynecol</i>. 2014;123(1):202-216.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/24463691/pubmed\" target=\"_blank\" id=\"24463691\">24463691</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22353976\"></a>ACOG Practice Bulletin No. 126: management of gynecologic issues in women with breast cancer. <i>Obstet Gynecol</i>. 2012;119(3):666-682. doi: 10.1097/AOG.0b013e31824e12ce.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/22353976/pubmed\" target=\"_blank\" id=\"22353976\">22353976</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Adler CH, &ldquo;Treatment of Restless Legs Syndrome With Gabapentin,&rdquo; <i>Clin Neuropharmacol</i>, 1997, 20(2):148-51.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/9099467/pubmed\" target=\"_blank\" id=\"9099467\">9099467</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17545753\"></a>Alonso-Navarro H, Rubio L, Jim&eacute;nez-Jim&eacute;nez FJ. Refractory hiccup: successful treatment with gabapentin. <i>Clin Neuropharmacol</i>. 2007;30(3):186-187.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/17545753/pubmed\" target=\"_blank\" id=\"17545753\">17545753</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/9099467/pubmed\" target=\"_blank\" id=\"9099467\">9099467</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Andrews CO and Fischer JH, &ldquo;Gabapentin: A New Agent for the Management of Epilepsy,&rdquo; <i>Ann Pharmacother</i>, 1994, 28(10):1188-96.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/7841578/pubmed\" target=\"_blank\" id=\"7841578\">7841578</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17393438\"></a>Arnold LM, Goldenberg DL, Stanford SB, et al. Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial. <i>Arthritis Rheum</i>. 2007;56(4):1336-1344.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/17393438/pubmed\" target=\"_blank\" id=\"17393438\">17393438</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"20402746\"></a>Attal N, Cruccu G, Baron R, et al, &quot;EFNS Guidelines on the Pharmacological Treatment of Neuropathic Pain: 2010 Revision,&quot; <i>Eur J Neurol</i>, 2010, 17(9):1113-e88.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/20402746/pubmed\" target=\"_blank\" id=\"20402746\">20402746</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23269131\"></a>Barr J, Fraser G, Puntillo K, et al, &ldquo;Clinical Practice Guidelines for the Management of Pain, Agitation, and Delirium in Adult Patients in the Intensive Care Unit,&rdquo; <i>Crit Care Med</i>, 2013, 41(1):263-306.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/23269131/pubmed\" target=\"_blank\" id=\"23269131\">23269131</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Borgelt LM, Hart FM, Bainbridge JL. Epilepsy during pregnancy: focus on management strategies. <i>Int J Womens Health</i>. 2016;8:505-517.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/27703396/pubmed\" target=\"_blank\" id=\"27703396\">27703396</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bourgeois BF, &ldquo;Antiepileptic Drugs in Pediatric Practice,&rdquo; <i>Epilepsia</i>, 1995, 36(Suppl 2):34-45.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/8784213/pubmed\" target=\"_blank\" id=\"8784213\">8784213</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21482920\"></a>Bril V, England J, Franklin GM, et al, &quot;Evidence-Based Guideline: Treatment of Painful Diabetic Neuropathy: Report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation,&quot; <i>Neurology</i>, 2011, 76(20):1758-65.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/21482920/pubmed\" target=\"_blank\" id=\"21482920\">21482920</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"18540923\"></a>Brower KJ, Myra Kim H, Strobbe S, Karam-Hage MA, Consens F, Zucker RA. A randomized double-blind pilot trial of gabapentin versus placebo to treat alcohol dependence and comorbid insomnia. <i>Alcohol Clin Exp Res</i>. 2008;32(8):1429-1438.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/18540923/pubmed\" target=\"_blank\" id=\"18540923\">18540923</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brown JT and Randall A, &ldquo;Gabapentin Fails to Alter P/Q-Type Ca2+ Channel-Mediated Synaptic Transmission in the Hippocampus <i>in vitro</i>,&rdquo; <i>Synapse</i>, 2005, 55(4):262-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/15668986/pubmed\" target=\"_blank\" id=\"15668986\">15668986</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"10642063\"></a>Bueller HA, Bernhard JD, Dubroff LM. Gabapentin treatment for brachioradial pruritus. <i>J Eur Acad Dermatol Venereol</i>. 1999;13(3):227-228.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/10642063/pubmed\" target=\"_blank\" id=\"10642063\">10642063</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Butt DA, Lock M, Lewis JE, et al, &ldquo;Gabapentin for the Treatment of Menopausal Hot Flashes: A Randomized Controlled Trial,&rdquo; <i>Menopause</i>, 2008, 15(2):310-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/17917611/pubmed\" target=\"_blank\" id=\"17917611\">17917611</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"26131874\"></a>Carvalho S, Sanches M, Alves R, Selores M. Brachioradial pruritus in a patient with cervical disc herniation and Parsonage-Turner syndrome. <i>An Bras Dermatol</i>. 2015;90(3):401-402.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/26131874/pubmed\" target=\"_blank\" id=\"26131874\">26131874</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"25577930\"></a>Centre for Clinical Practice at NICE (UK). Neuropathic Pain: The Pharmacological Management of Neuropathic Pain in Adults in Non-specialist Settings [Internet]. London: National Institute for Health and Care Excellence, (UK); 2013 Nov. Available from <a href=\"http://www.ncbi.nlm.nih.gov/books/NBK266257\" target=\"_blank\">http://www.ncbi.nlm.nih.gov/books/NBK266257</a>.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/25577930/pubmed\" target=\"_blank\" id=\"25577930\">25577930</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"26131874\"></a>Davanzo R, Dal Bo S, Bua J, Copertino M, Zanelli E, Matarazzo L. Antiepileptic drugs and breastfeeding. <i>Ital J Pediatr</i>. 2013;39:50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/26131874/pubmed\" target=\"_blank\" id=\"26131874\">26131874</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"26300519\"></a>Doleman B, Heinink TP, Read DJ, Faleiro RJ, Lund JN, Williams JP. A systematic review and meta-regression analysis of prophylactic gabapentin for postoperative pain. <i>Anaesthesia</i>. 2015;70(10):1186-1204.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/26300519/pubmed\" target=\"_blank\" id=\"26300519\">26300519</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"25575710\"></a>Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. <i>Lancet Neurol</i>. 2015;14(2):162-173.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/25575710/pubmed\" target=\"_blank\" id=\"25575710\">25575710</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fischer JH, Barr AN, Rogers SL, et al, &ldquo;Lack of Serious Toxicity Following Gabapentin Overdose,&rdquo; <i>Neurology</i>, 1994, 44(5):982-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/8190316/pubmed\" target=\"_blank\" id=\"8190316\">8190316</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"18052562\"></a>Furieri FA, Nakamura-Palacios EM.Gabapentin reduces alcohol consumption and craving: a randomized, double-blind, placebo-controlled trial. <i>J Clin Psychiatry</i>. 2007;68(11):1691-1700.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/18052562/pubmed\" target=\"_blank\" id=\"18052562\">18052562</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Garcia-Borreguero D, Silber MH, Winkelman JW, et al. Guidelines for the first-line treatment of restless legs syndrome/Willis-Ekbom disease, prevention and treatment of dopaminergic augmentation: a combined task force of the IRLSSG, EURLSSG, and the RLS-foundation. <i>Sleep Med</i>. 2016;21:1-11. doi: 10.1016/j.sleep.2016.01.017.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/27448465/pubmed\" target=\"_blank\" id=\"27448465\">27448465</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"26426314\"></a>Gibson P, Wang G, McGarvey L, Vertigan AE, Altman KW, Birring SS; CHEST Expert Cough Panel. Treatment of Unexplained Chronic Cough: CHEST Guideline and Expert Panel Report. <i>Chest</i>. 2016;149(1):27-44. doi:10.1378/chest.15-1496.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/26426314/pubmed\" target=\"_blank\" id=\"26426314\">26426314</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Goa KL and Sorkin EM, &ldquo;Gabapentin: A Review of Its Pharmacological Properties and Clinical Potential in Epilepsy,&rdquo; <i>Drugs</i>, 1993, 46(3):409-27.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/7693432/pubmed\" target=\"_blank\" id=\"7693432\">7693432</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15575002\"></a>Gunal AI, Ozalp G, Yoldas TK, Gunal SY, Kirciman E, Celiker H. Gabapentin therapy for pruritus in haemodialysis patients: a randomized, placebo-controlled, double-blind trial. <i>Nephrol Dial Transplant</i>. 2004;19(12):3137-3139.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/15575002/pubmed\" target=\"_blank\" id=\"15575002\">15575002</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"12576259\"></a>Guttuso T Jr, Kurlan R, McDermott MP, Kieburtz K. Gabapentin&rsquo;s effects on hot flashes in postmenopausal women: A randomized, controlled trial. <i>Obstet Gynecol</i>. 2003;101(2):337.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/12576259/pubmed\" target=\"_blank\" id=\"12576259\">12576259</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Happe S, Sauter C, Klosch G, et al, &ldquo;Gabapentin Versus Ropinirole in the Treatment of Idiopathic Restless Legs Syndrome,&rdquo; <i>Neuropsychobiology</i>, 2003, 48(2):82-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/14504416/pubmed\" target=\"_blank\" id=\"14504416\">14504416</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15308440\"></a>Hern&aacute;ndez JL, Pajar&oacute;n M, Garc&iacute;a-Regata O, Jim&eacute;nez V, Gonz&aacute;lez-Mac&iacute;as J, Ramos-Est&eacute;banez C. Gabapentin for intractable hiccup. <i>Am J Med</i>. 2004;117(4):279-281.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/15308440/pubmed\" target=\"_blank\" id=\"15308440\">15308440</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23585393\"></a>Helld&eacute;n A, Odar-Cederl&ouml;f I, Nilsson G, et al. Renal function estimations and dose recommendations for dabigatran, gabapentin and valaciclovir: a data simulation study focused on the elderly. <i>BMJ Open</i>. 2013;3(4):pii: e002686. doi: 10.1136/bmjopen-2013-002686.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/23585393/pubmed\" target=\"_blank\" id=\"23585393\">23585393</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Holmes LB and Hernandez-Diaz S, &quot;Newer Anticonvulsants: Lamotrigine, Topiramate, and Gabapentin,&quot; <i>Birth Defects Res A Clin Mol Teratol</i>, 2012, 94(8):599-606.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/22730257/pubmed\" target=\"_blank\" id=\"22730257\">22730257</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/10891521/pubmed\" target=\"_blank\" id=\"10891521\">10891521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17360149\"></a>Jatzko A, Stegmeier-Petroianu A, Petroianu GA. Alpha-2-delta ligands for singultus (hiccup) treatment: Three case reports. <i>Journal of Pain and Symptom Management.</i> 2007; 33(6):756-760.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/17360149/pubmed\" target=\"_blank\" id=\"17360149\">17360149</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"16709503\"></a>Kanitakis J. Brachioradial pruritus: report of a new case responding to gabapentin. <i>Eur J Dermatol</i>. 2006;16(3):311-312.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/16709503/pubmed\" target=\"_blank\" id=\"16709503\">16709503</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Khurana DS, Riviello J, Helmers S, et al, &ldquo;Efficacy of Gabapentin Therapy in Children With Refractory Partial Seizures,&rdquo; <i>J Pediatr</i>, 1996, 128(6):829-33.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/8648543/pubmed\" target=\"_blank\" id=\"8648543\">8648543</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Laird MA and Gidal BE, &ldquo;Use of Gabapentin in the Treatment of Neuropathic Pain,&rdquo; <i>Ann Pharmacother</i>, 2000, 34(6):802-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/10860142 /pubmed\" target=\"_blank\" id=\"10860142 \">10860142 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lee DO, Steingard RJ, Cesena M, et al, &ldquo;Behavioral Side Effects of Gabapentin in Children,&rdquo; <i>Epilepsia</i>, 1996, 37(1):87-90.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/8603631/pubmed\" target=\"_blank\" id=\"8603631\">8603631</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Leiderman D, Garofalo E, and LaMoreaux L, &ldquo;Gabapentin Patients With Absence Seizures: Two Double-Blind, Placebo Controlled Studies,&rdquo; <i>Epilepsia</i>, 1993, 34(Suppl 6):45.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23435567\"></a>L'Esp&eacute;rance S, Frenette S, Dionne A, Dionne JY; Comit&eacute; de l&rsquo;&eacute;volution des pratiques en oncologie (CEPO). Pharmacological and non-hormonal treatment of hot flashes in breast cancer survivors: CEPO review and recommendations. <i>Support Care Cancer</i>. 2013;21(5):1461-1474. doi: 10.1007/s00520-013-1732-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/23435567/pubmed\" target=\"_blank\" id=\"23435567\">23435567</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"27450233\"></a>Li L, Xu L, Wu J, Dong L, Zhao S, Zheng Q. Comparative efficacy of nonhormonal drugs on menopausal hot flashes. <i>Eur J Clin Pharmacol</i>. 2016;72(9):1051-1058.doi: 10.1007/s00228-016-2090-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/27450233/pubmed\" target=\"_blank\" id=\"27450233\">27450233</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19129205\"></a>Loprinzi CL, Dueck AC, Khoyratty BS, et al. A phase III randomized, double-blind, placebo-controlled trial of gabapentin in the management of hot flashes in men (N00CB). <i>Ann Oncol</i>. 2009;20(3):542-549.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/19129205/pubmed\" target=\"_blank\" id=\"19129205\">19129205</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19332723\"></a>Loprinzi CL, Sloan J, Stearns V, et al. Newer antidepressants and gabapentin for hot flashes: an individual patient pooled analysis. <i>J Clin Oncol</i>. 2009;27(17):2831-2837.doi: 10.1200/JCO.2008.19.6253.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/19332723/pubmed\" target=\"_blank\" id=\"19332723\">19332723</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24190578\"></a>Mason BJ, Quello S, Goodell V, Shadan F, Kyle M, Begovic A. Gabapentin treatment for alcohol dependence: a randomized clinical trial. <i>JAMA Intern Med</i>. 2014;174(1):70-77.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/24190578/pubmed\" target=\"_blank\" id=\"24190578\">24190578</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mellick LB and Mellick GA, &ldquo;Successful Treatment of Reflex Sympathetic Dystrophy With Gabapentin,&rdquo; <i>Am J Emerg Med</i>, 1995, 13(1):96.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/7832967/pubmed\" target=\"_blank\" id=\"7832967\">7832967</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23093831\"></a>Menon M. Gabapentin in the treatment of persistent hiccups in advanced malignancy. <i>Indian Journal of Palliative Care.</i> 2012;18(2):138-140.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/23093831/pubmed\" target=\"_blank\" id=\"23093831\">23093831</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24771480\"></a>Moore RA, Wiffen PJ, Derry S, Toelle T, Rice AS. Gabapentin for chronic neuropathic pain and fibromyalgia in adults. <i>Database Syst Rev</i>. 2014;(4):CD007938.doi: 10.1002/14651858.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/24771480/pubmed\" target=\"_blank\" id=\"24771480\">24771480</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"10866495\"></a>Moretti R, Torre P, Antonello RM, Nasuelli D, Cazzato G. Treatment of chronic hiccups: new perspectives. <i>Eur J Neurol</i>. 1999;6(5):617-620.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/10866495/pubmed\" target=\"_blank\" id=\"10866495\">10866495</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"14998440\"></a>Moretti R, Torre P, Antonello RM, et al. Gabapentin as a drug therapy of intractable hiccup because of vascular lesion: a three-year follow up. <i>Neurologist</i>. 2004;10(2):102-106.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/14998440/pubmed\" target=\"_blank\" id=\"14998440\">14998440</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19485969\"></a>Myrick H, Malcolm R, Randall PK, et al. A double-blind trial of gabapentin versus lorazepam in the treatment of alcohol withdrawal. <i>Alcohol Clin Exp Res</i>. 2009;33(9):1582-1588.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/19485969/pubmed\" target=\"_blank\" id=\"19485969\">19485969</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17679749\"></a>Naini AE, Harandi AA, Khanbabapour S, Shahidi S, Seirafiyan S, Mohseni M. Gabapentin: a promising drug for the treatment of uremic pruritus. <i>Saudi J Kidney Dis Transpl</i>. 2007;18(3):378-381.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/17679749/pubmed\" target=\"_blank\" id=\"17679749\">17679749</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Neurontin (gabapentin) [prescribing information]. New York, NY: Pfizer; February 2018.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"27043168\"></a>Nofal E, Farag F, Nofal A, et al. Gabapentin: A promising therapy for uremic pruritus in hemodialysis patients: A randomized-controlled trial and review of literature. <i>J Dermatolog Treat</i>. 2016;27(6):515-519.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/27043168/pubmed\" target=\"_blank\" id=\"27043168\">27043168</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"26382310\"></a>North American Menopause Society (NAMS). Nonhormonal management of menopause-associated vasomotor symptoms: 2015 position statement of The North American Menopause Society. <i>Menopause. </i>2015;22(11).<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/26382310/pubmed\" target=\"_blank\" id=\"26382310\">26382310</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ohman I, Vitols S, and Tomson T, &quot;Pharmacokinetics of Gabapentin During Delivery, in the Neonatal Period, and Lactation: Does a Fetal Accumulation Occur During Pregnancy?&quot; <i>Epilepsia</i>, 2005, 46(10):1621-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/16190933/pubmed\" target=\"_blank\" id=\"16190933\">16190933</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"18981399\"></a>Ong AM, Tan CS, Foo MW, Kee TY. Gabapentin for intractable hiccups in a patient undergoing peritoneal dialysis. <i>Perit Dial Int</i>. 2008;28(6):667-668.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/18981399/pubmed\" target=\"_blank\" id=\"18981399\">18981399</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"10440462\"></a>Pande AC, Davidson JR, Jefferson JW, et al. Treatment of social phobia with gabapentin: a placebo-controlled study. <i>J Clin Psychopharmacol</i>. 1999;19(4):341-348.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/10440462/pubmed\" target=\"_blank\" id=\"10440462\">10440462</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17505569\"></a>Peng PW, Wijeysundera DN, Li CC. Use of gabapentin for perioperative pain control - a meta-analysis. <i>Pain Res Manag</i>. 2007;12(2):85-92.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/17505569/pubmed\" target=\"_blank\" id=\"17505569\">17505569</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"10777198\"></a>Petroianu G, Hein G, Stegmeier-Petroianu A, Bergler W, R&uuml;fer R. Gabapentin &quot;add-on therapy&quot; for idiopathic chronic hiccup (ICH). <i>J Clin Gastroenterol</i>. 2000;30(3):321-324.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/10777198/pubmed\" target=\"_blank\" id=\"10777198\">10777198</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"25553600\"></a>Picchietti DL, Hensley JG, Bainbridge JL, et al. Consensus clinical practice guidelines for the diagnosis and treatment of restless legs syndrome/Willis-Ekbom disease during pregnancy and lactation. <i>Sleep Med Rev</i>. 2015;22:64-77.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/25553600/pubmed\" target=\"_blank\" id=\"25553600\">25553600</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24149930\"></a>Pinkerton JV, Kagan R, Portman D, et al. Phase 3 randomized controlled study of gastroretentive gabapentin for the treatment of moderate-to-severe hot flashes in menopause. <i>Menopause.</i> 2014;21(6):567-573.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/24149930/pubmed\" target=\"_blank\" id=\"24149930\">24149930</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"26416344\"></a>Pongcharoen P, Fleischer AB Jr. An evidence-based review of systemic treatments for itch. <i>Eur J Pain</i>. 2016;20(1):24-31.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/26416344/pubmed\" target=\"_blank\" id=\"26416344\">26416344</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"27999003\"></a>Pop-Busui R, Boulton AJM, Feldman EL, et al. Diabetic neuropathy: A position statement by the American Diabetes Association. <i>Diabetes Care. </i>2017;40:136-154.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/27999003/pubmed\" target=\"_blank\" id=\"27999003\">27999003</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"14581957\"></a>Porzio G, Aielli F, Narducci F, et al. Hiccup in patients with advanced cancer successfully treated with gabapentin: report of three cases. <i>N Z Med J</i>. 2003;116(1182):1-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/14581957/pubmed\" target=\"_blank\" id=\"14581957\">14581957</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"20414106\"></a>Porzio G, Aielli F, Verna L, et al. Gabepentin in the treatment of hiccups in patients with advanced cancer: A 5-year experience. <i>Clin Neuropharm. </i>2010;33:179-180.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/20414106/pubmed\" target=\"_blank\" id=\"20414106\">20414106</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19212903\"></a>Razeghi E, Eskandari D, Ganji MR, Meysamie AP, Togha M, Khashayar P. Gabapentin and uremic pruritus in hemodialysis patients. <i>Ren Fail</i>. 2009;31(2):85-90.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/19212903/pubmed\" target=\"_blank\" id=\"19212903\">19212903</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"16816054\"></a>Reddy SY, Warner H, Guttuso T Jr, et al. Gabapentin, estrogen, and placebo for treating hot flushes: A randomized controlled trial. <i>Obstet Gynecol. </i>2006;108(1):41.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/16816054/pubmed\" target=\"_blank\" id=\"16816054\">16816054</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rose MA and Kam PCA, &ldquo;Gabapentin: Pharmacology and Its Use in Pain Management,&rdquo; <i>Anaesthesia</i>, 2002, 57:451-62.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/11966555 /pubmed\" target=\"_blank\" id=\"11966555 \">11966555 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rosenberg JM, Harrell C, Ristic H, et al, &ldquo;The Effect of Gabapentin on Neuropathic Pain,&rdquo; <i>Clin J Pain</i>, 1997, 13(3):251-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/9303258 /pubmed\" target=\"_blank\" id=\"9303258 \">9303258 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rowbotham M, Harden N, Stacey B, et al, &ldquo;Gabapentin for the Treatment of Postherpetic Neuralgia: A Randomized Controlled Trial,&rdquo; <i>JAMA</i>, 1998, 280(21):1837-42.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/9846778 /pubmed\" target=\"_blank\" id=\"9846778 \">9846778 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24284851\"></a>Rudroju N, Bansal D, Talakokkula ST, et al. Comparative efficacy and safety of six antidepressants and anticonvulsants in painful diabetic neuropathy: a network meta-analysis. <i>Pain Physician</i>. 2013;16(6):705-714.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/24284851/pubmed\" target=\"_blank\" id=\"24284851\">24284851</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22951084\"></a>Ryan NM, Birring SS, Gibson PG. Gabapentin for refractory chronic cough: a randomised, double-blind, placebo-controlled trial. <i>Lancet</i>. 2012;380(9853):1583-1589.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/22951084/pubmed\" target=\"_blank\" id=\"22951084\">22951084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Saletu M, Anderer P, Saletu-Zyhlarz GM, et al, &ldquo;Comparative Placebo-Controlled Polysomnographic and Psychometric Studies on the Acute Effects of Gabapentin Versus Ropinirole in Restless Legs Syndrome,&rdquo;<i>J Neural Transm</i>, 2010, 117(4):463-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/20049491/pubmed\" target=\"_blank\" id=\"20049491\">20049491</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22497967\"></a>Sandercock D, Cramer M, Biton V, Cowles VE. A gastroretentive gabapentin formulation for the treatment of painful diabetic peripheral neuropathy: Efficacy and tolerability in a double-blind, randomized, controlled clinical trial. <i>Diabetes Research and Clinical Practice</i>. 2012;97:438-445.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/22497967/pubmed\" target=\"_blank\" id=\"22497967\">22497967</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19171730\"></a>Sandercock D, Cramer M, Wu J, et al. Gabapentin extended release for the treatment of painful diabetic peripheral neuropathy: efficacy and tolerability in a double-blind, randomized, controlled clinical trial. <i>Diabetes Care</i>. 2009;32(2):e20. doi: 10.2337/dc08-1450.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/19171730/pubmed\" target=\"_blank\" id=\"19171730\">19171730</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"18090442\"></a>Schuchmann JA, Browne BA. Persistent hiccups during rehabilitation hospitalization: three case reports and review of the literature. <i>Am J Phys Med Rehabil</i>. 2007;86(12):1013-1018.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/18090442/pubmed\" target=\"_blank\" id=\"18090442\">18090442</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Short C and Cooke L, &ldquo;Hypomania Induced by Gabapentin,&rdquo; <i>Br J Psychiatry</i>, 1995, 166(5):679-80.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/7620760/pubmed\" target=\"_blank\" id=\"7620760\">7620760</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sills GJ, &ldquo;The Mechanisms of Action of Gabapentin and Pregabalin,&rdquo; <i>Curr Opin Pharmacol</i>, 2006, 6(1):108-13.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/16376147/pubmed\" target=\"_blank\" id=\"16376147\">16376147</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"26444994\"></a>Stuenkel CA, Davis SR, Gompel A, et al. Treatment of symptoms of the menopause: an Endocrine Society Clinical Practice Guideline. <i>J Clin Endocrinol Metab</i>. 2015;100(11):3975-4011. doi: 10.1210/jc.2015-2236.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/26444994/pubmed\" target=\"_blank\" id=\"26444994\">26444994</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"VA.DoD.2015\"></a>The Management of Substance Use Disorders Work Group; US Department of Veterans Affairs (VA); US Department of Defense (DoD). VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders. <a href=\"http://www.healthquality.va.gov/guidelines/MH/sud/VADoDSUDCPGRevised22216.pdf\" target=\"_blank\">http://www.healthquality.va.gov/guidelines/MH/sud/VADoDSUDCPGRevised22216.pdf</a>. Published December 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19302896\"></a>Toulis KA, Tzellos T, Kouvelas D, Goulis DG. Gabapentin for the treatment of hot flashes in women with natural or tamoxifen-induced menopause: a systematic review and meta-analysis. <i>Clin Ther</i>. 2009;31(2):221-235.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/19302896/pubmed\" target=\"_blank\" id=\"19302896\">19302896</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Veiby G, Bj&oslash;rk M, Engelsen BA, Gilhus NE. Epilepsy and recommendations for breastfeeding. <i>Seizure</i>. 2015;28:57-65.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/25837494/pubmed\" target=\"_blank\" id=\"25837494\">25837494</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vignatelli L, Billiard M, Clarenbach P, et al, &ldquo;EFNS Guidelines on Management of Restless Leg Syndrome and Periodic Limb Movement Disorder in Sleep,&rdquo; <i>Eur J Neurol</i>, 2006, 13(10):1049-65.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/16987157/pubmed\" target=\"_blank\" id=\"16987157\">16987157</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22790094\"></a>Weisshaar E, Szepietowski JC, Darsow U, et al. European guideline on chronic pruritus. <i>Acta Derm Venereol</i>. 2012;92(5):563-581.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/22790094/pubmed\" target=\"_blank\" id=\"22790094\">22790094</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15099389\"></a>Winhoven SM, Coulson IH, Bottomley WW. Brachioradial pruritus: response to treatment with gabapentin. <i>Br J Dermatol</i>. 2004;150(4):786-787.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/15099389/pubmed\" target=\"_blank\" id=\"15099389\">15099389</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"20629833\"></a>Yilmaz S, Ceyhan AM, Baysal Akkaya V. Brachioradial pruritus successfully treated with gabapentin. <i>J Dermatol</i>. 2010;37(7):662-665.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/20629833/pubmed\" target=\"_blank\" id=\"20629833\">20629833</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23921329\"></a>Yu L, Ran B, Li M, Shi Z. Gabapentin and pregabalin in the management of postoperative pain after lumbar spinal surgery: a systematic review and meta-analysis. <i>Spine (Phila Pa 1976)</i>. 2013;38(22):1947-1952.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gabapentin-drug-information/abstract-text/23921329/pubmed\" target=\"_blank\" id=\"23921329\">23921329</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8483 Version 298.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F175023\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F50769812\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F175060\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F175027\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment (Adult)\" href=\"#F50991466\" class=\"outlineLink\">Dosing: Renal Impairment (Adult)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment (Adult)\" href=\"#F50988788\" class=\"outlineLink\">Dosing: Hepatic Impairment (Adult)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F175044\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment (Pediatric)\" href=\"#F51110605\" class=\"outlineLink\">Dosing: Renal Impairment (Pediatric)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment (Pediatric)\" href=\"#F51110606\" class=\"outlineLink\">Dosing: Hepatic Impairment (Pediatric)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F175028\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F174997\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F174981\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F28799619\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F10916634\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F175001\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F175000\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25726013\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F175068\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F174988\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F175005\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F174985\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299373\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F174990\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F175018\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F174993\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F175008\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F175009\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F175010\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F174995\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F174984\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F175004\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics: Additional Considerations\" href=\"#F51196078\" class=\"outlineLink\">Pharmacodynamics/Kinetics: Additional Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F175007\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F175011\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8483|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=gabapentin-patient-drug-information\" class=\"drug drug_patient\">Gabapentin: Patient drug information</a></li><li><a href=\"topic.htm?path=gabapentin-pediatric-drug-information\" class=\"drug drug_pediatric\">Gabapentin: Pediatric drug information</a></li></ul></div></div>","javascript":null}